MHC class II molecules are central to the adaptive immune response, serving as the means by which antigen-presenting cells, notably dendritic cells, display processed peptides to CD4+ T cells. This ...

Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...